ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

D. Evstratov1, P. Zharkov1, N. Myakova1

1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Abstract Number: PB1102

Meeting: ISTH 2021 Congress

Theme: Venous Thromboembolism » Cancer Associated Thrombosis

Background: Lymphoma is the third most common cancer in children and adolescents. Venous thromboembolism (VTE) is a frequent complication in pediatric patients with lymphomas, but there is lack of data about risk factors for symptomatic VTE (sVTE) in this cohort of patients.

Aims: To evaluate risk factors for VTE in children and adolescents with lymphomas.

Methods: Our study is a monocentric retrospective analysis of 262 patients aged <18 years with lymphoma that were treated in our Center since 2013 to 2019 year. The epidemiological characteristics of patients are presented in table 1.

Characteristic Patients without sVTE (%) Patients with sVTE (%) P, Chi-square
ABO – Group O 84 (34.9%) 3 (14.3%) P=0.057
ABO – Group “Non-O” 157 (65.1%) 18 (85.7%)
Hodgkin lymphoma 75 (31.1%) 9 (42.9%) P=0.27
Non-Hodgkin lymphoma 166 (68.9%) 12 (57.1%)
Mediastinal involvement – 159 (66%) 6 (28.6%)  
P=0.001
Mediastinal involvement + 82 (34%) 15 (71.4%)
Intensive care unit treatment during the first 30 days of hospitalization – 200 (83%) 14 (66.7%)  

P=0.064

Intensive care unit treatment during the first 30 days of hospitalization + 41 (17%) 7 (33.3%)
Male 165 (68.5%) 7 (33.3%) P=0.87
Female 76 (31.5%) 14 (66.7%)

Epidemiological characteristics of children and adolescents with lymphomas
We took only sVTE as the event, data of asymptomatic VTE was censored. Patients were followed since the start of treatment to sVTE, relapse, death, +100 day after allogenic hematopoietic stem cell transplantation or loss to follow-up, whatever came. VTE diagnosed before the start of the treatment was recorded as the time 0. The median time of follow up was 2,18 years (IQR 0,71-3,85 years). Risk factors were analyzed by univariate and multivariate analysis with logistic regression. ROC-analysis was used for the determination of optimal cutoff. P-value <0,05 was considered as significant.

Results: Among all patients sVTE was diagnosed in 21 (8%, 95%CI: 4,73-11,3). Median time to diagnosis was 22 (IQR 17-36,5) days. The optimal cutoff for duration of treatment in the intensive care unit during the first 30 days was >2 days. The optimal cutoff for the volume of mediastinal lymphadenopathy was 250 ml. The optimal cutoff for age was ≥12 years. Results of the univariate and multivariate analysis are presented in the table 2.

Characteristic Univariate analysis Multivariate analysis
Odds ratio (95%CI) p-value Odds ratio (95%CI) p-value
ABO group “Non-O” 3.2 (0.925-11.28) 0.066 4.86 (1.26-18.65) 0.02
Volume of mediastinal lymphadenopathy ≥250 ml 6.3 (2.49-16.1) 0.0001 4.38 (1.59-12.1) 0.004
ICU hospitalization ≥2 days 3.6 (1.4-9.8) 0.01 2.92 (0.98-8.68) 0.053
Age ≥12 years 8.8 (2.5-30.8) 0.001 6.7 (1.8-24.9) 0.004

Univariate and multivariate analysis of risk factors for sVTE in children and adolescents with lymphomas.

Conclusions: Blood group “Non-O”, volume of mediastinal lymphadenopathy ≥250 ml and age ≥12 years are independent risk factors for sVTE in children and adolescents with lymphomas. These factors could be used for further studies of primary antithrombotic prophylaxis in this cohort of patients.

To cite this abstract in AMA style:

Evstratov D, Zharkov P, Myakova N. Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/risk-factors-for-symptomatic-venous-thromboembolism-in-children-and-adolescents-with-lymphomas-2/. Accessed May 20, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/risk-factors-for-symptomatic-venous-thromboembolism-in-children-and-adolescents-with-lymphomas-2/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley